"金智奖"旨在树立高质量发展标杆，引导上市公司聚焦主业、持续创新、践行社会责任，推动资本向优质企业集聚。本届评选中，金融界上市公司研究院紧 密契合"十五五"规划建议中"提升上市公司质量"的要求，将高质量发展内核分解为社会责任、实业贡献、投资回报、成长前景、创新效率、杰出品牌六大维 度，以企业财务数据和公开信息为基础建立量化分析模型，最终覆盖A股、港股及中概股超8000家企业，评选出近200家获奖企业。 例如，公司历时七年，研发出源自中国健康婴儿肠道的优质菌株LPB27并落地产品，菌株已获三项中国发明专利；递交"有助于维持正常的血小板聚集功 能，有益于血流健康"新功能申报，成为行业内第一个递交新功能申报及产品注册申请的企业；自主建成全自动在线干血斑检测中心，实现只用少量人体指 尖末梢血，即可对多种维生素进行准确定量。 "杰出品牌奖"以品牌综合实力为核心评判标准，覆盖市场认可度、产品服务创新力、行业影响力及社会责任等关键指标，旨在树立行业品质与创新标杆，为 客户提供可信赖的选择指引，助力行业规范化升级与高质量发展。 截止目前，公司已获得489项专利，包括144项原料及配方等发明专利。依托自建的营养健康研究院以及外 ...

转自：扬子晚报 2025年12月27日，由新华报业传媒集团主办的第十六届新华高峰会在南京新华报业传媒集团智汇星空剧 场隆重举行。本届峰会以"品牌江苏挑大梁 创新发展走在前"为主题，汇聚政府领导、学者专家、企业 家代表及各界精英，共同探讨"十五五"中国经济新引擎与江苏品牌发展新路径。峰会现场发布了"新华 致敬·2025江苏科创领军示范案例"，江苏仅三生物科技有限公司（下称"GeneIII仅三生物"）凭借其在合 成生物制造领域的突出创新与产业贡献，成为获奖企业之一。GeneIII仅三生物创始合伙人兼市场副总 何儒俊代表企业受邀出席并上台领奖。 自创立以来，新华高峰会已成功举办十五届，始终站在时代前沿，聚焦经济热点，为江苏乃至长三角地 区的高质量发展建言献策，已成为国内颇具影响力的高端思想交流与品牌赋能平台之一。本届峰会着 眼"十五五"新起点，特别强调科技创新在塑造新质生产力、构建新发展格局中的核心引擎地位。中国人 民大学原副校长、国家金融研究院院长吴晓求教授在发表主旨演讲时指出："江苏作为经济大省与科技 强省，正处在从要素驱动向创新驱动深度转型的关键期。未来的核心竞争力，将愈发体现在能否在生物 制造、人工智能、新 ...

12月22日，技源集团涨4.84%，成交额8742.26万元。两融数据显示，当日技源集团获融资买入额785.04 万元，融资偿还967.91万元，融资净买入-182.87万元。截至12月22日，技源集团融资融券余额合计 6576.92万元。 融资方面，技源集团当日融资买入785.04万元。当前融资余额6569.71万元，占流通市值的5.87%。 融券方面，技源集团12月22日融券偿还0.00股，融券卖出2400.00股，按当日收盘价计算，卖出金额6.92 万元；融券余量2500.00股，融券余额7.21万元。 资料显示，技源集团股份有限公司位于上海市徐汇区钦州北路1089号54栋5层，成立日期2002年9月17 日，上市日期2025年7月23日，公司主营业务涉及膳食营养补充产品研发创新及产业化。主营业务收入 构成为：营养原料34.70%，制剂15.24%，营养原料:HMB14.08%，制剂:片剂10.59%，营养原料:氨基葡 萄糖9.43%，营养原料:硫酸软骨素7.07%，营养原料:其他4.12%，制剂:硬胶囊1.68%，制剂:其他 1.33%，制剂:软胶囊1.32%，制剂:粉剂0.32%，其他(补充)0.1 ...

编号:IR-RCL-2025-115 市场地位确认声明 Market Position Confirmation Statement 近日，艾瑞咨询基于对苏糖酸镁补镁片、高端孕妇补铁片、高端高含量护肝片和进口小分子胶原蛋 白肽等多个行业的深入研究与技术分析，确认 LOSOKI "苏糖酸镁补镁片全网销量第一""高端高含 量护肝片全网销量第一""高端进口孕妇补铁片全网销量第一""进口小分子胶原蛋白肽全网销量领 先"的市场地位。艾瑞咨询通过严谨的行业调研、企业信息对比评估、专家访谈等 多维研究方法 ， 充分肯定了 LOSOKI 在健康消费领域强大的市场竞争力。 HOSOFT 77 Frest (1) 全网销量竞 询 咨 x 瑞 艾瑞数智旗下品牌 - 证书数据来源：根据艾瑞咨询针对苏糖酸镁补镁片行业的研究,通过对全国范围内(不包含港澳台)在售苏糖酸镁补镁片产 品的市场情况进行对比分析，评估线上销量（销量以总销售件数计，包含天猫、京东、抖音等电商平台）,得出：LOSOKI苏 糖酸镁补镁片全网销量第一;苏糖酸镁补镁片指产品成分中含有苏糖酸镁,且产品剂型为片剂的补镁类保健品或膳食营养补 充剂。 统计时间:2025年1月至2 ...

截至12月7日，技源集团股东户数2.40万，较上期减少6.73%；人均流通股1618股，较上期增加7.21%。 2025年1月-9月，技源集团实现营业收入7.97亿元，同比增长7.58%；归母净利润1.17亿元，同比减少 14.72%。 融券方面，技源集团12月19日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量100.00股，融券余额2749.00元。 资料显示，技源集团股份有限公司位于上海市徐汇区钦州北路1089号54栋5层，成立日期2002年9月17 日，上市日期2025年7月23日，公司主营业务涉及膳食营养补充产品研发创新及产业化。主营业务收入 构成为：营养原料34.70%，制剂15.24%，营养原料:HMB14.08%，制剂:片剂10.59%，营养原料:氨基葡 萄糖9.43%，营养原料:硫酸软骨素7.07%，营养原料:其他4.12%，制剂:硬胶囊1.68%，制剂:其他 1.33%，制剂:软胶囊1.32%，制剂:粉剂0.32%，其他(补充)0.11%。 12月19日，技源集团涨0.84%，成交额2037.74万元。两融数据显示，当日技源集团获融资买入额397. ...

Core Viewpoint - Qingmu Technology, a leading domestic internet e-commerce service provider, is enhancing its market competitiveness through a significant acquisition in the health sector by acquiring 65.83% of Vitalis Pharma AS for 2.12 billion RMB [2][3]. Acquisition Details - The acquisition will be executed by Qingmu's wholly-owned subsidiary, Qingmu PTE. LTD., in two steps: purchasing 49.0662% of Vitalis for approximately 1.06 billion RMB and subscribing to 32.9157% of newly issued shares for the same amount [3]. - Vitalis, established in 2005 in Oslo, Norway, specializes in high-end dietary supplements, including products like seal oil, fish oil, astaxanthin, and coenzyme Q10 [3]. Financial Performance of Vitalis - Vitalis reported revenues of 151.43 million NOK and 97.94 million NOK for 2024 and the first half of 2025, respectively, with net profits of 28.55 million NOK and 23.31 million NOK [4]. - The profit target for Vitalis in 2025 is set at no less than 31 million NOK [4]. Performance Commitments - The acquisition includes performance commitments, requiring Vitalis to achieve a net profit of at least 41.85 million NOK by 2027 and 56.50 million NOK by 2028, representing a growth of no less than 35% year-over-year [5]. - The acquisition price of 300 million NOK is expected to create significant goodwill, which carries a risk of impairment [5]. Strategic Goals - The acquisition aims to implement the company's brand incubation and management strategy, enhancing its capabilities in brand management, product development, and supply chain management in the health sector [5]. - Qingmu Technology plans to increase investments in brand incubation and management, focusing on health consumer products through various strategies, including joint ventures and acquisitions of overseas brands [5]. Revenue Growth - In the first half of 2025, Qingmu's brand incubation and management business generated approximately 230 million RMB, marking an 86.5% year-over-year increase, with its contribution to overall revenue rising from 22.9% to 34.8% [6]. - The brands Cumlaude Lab and ZUCCARI significantly contributed to this revenue growth, achieving over 70% and 95% year-over-year increases, respectively [6]. Overall Company Performance - For the first three quarters of 2025, Qingmu Technology reported revenues of 1.021 billion RMB, a 26.34% increase year-over-year, and a net profit of 79.62 million RMB, up 10.22% [7]. - The company's gross margin has improved significantly, reaching 56.33% in the first three quarters of 2025, up 5.25 percentage points from the same period in 2024 [8].

Group 1: Organizational Structure and Strategy - The company has made a series of adjustments to its organizational structure over the past two years, establishing a brand division that manages the entire cycle from product development to market promotion and sales [2] - Future organizational optimizations will focus more on business empowerment, with no major changes expected overall [2] Group 2: Online and Offline Development Strategies - Online, Douyin is the largest platform for VDS industry sales, maintaining rapid growth, while Tmall and JD.com together account for approximately 60% of the market share [2][3] - The company plans to optimize operational strategies and enhance social media penetration, focusing on consumer needs across different channels to drive product iteration and brand asset optimization [2] - Offline, the company aims to strengthen product capabilities through digital infrastructure in pharmacies and new commercial delivery models, enhancing operational and service capabilities [2] Group 3: Revenue Structure and Market Insights - Currently, Douyin accounts for about 20% of online channel revenue, while Tmall and JD.com together account for approximately 60% [3] - The cross-border market constitutes about 70% of the company's revenue, with the domestic market making up the remaining 30% [3] - The company will focus on product research and innovation to meet the increasingly diverse consumer demands, particularly in the top ten stable product categories [3] Group 4: Sales Expenses and Market Growth - Sales expenses are categorized into two types: A-class expenses for brand building across all channels and B-class expenses for sales conversion support, with a short-term decrease in sales expense ratio being challenging [3] - The industry still has growth potential in China due to increasing penetration rates and the expansion of new consumer groups [3] Group 5: Brand Matrix and Positioning - The company adheres to a multi-brand, full-category strategy, with the main brand "汤臣倍健" targeting the entire population [3] - The brands "健力多" and "lifespace" have shown good development, each accounting for over 10% of the company's revenue [3]

Group 1 - The core viewpoint of the news is that 技源集团 (TechSource Group) experienced a decline in stock price and a net outflow in financing on November 17, with a trading volume of 36.29 million yuan and a financing balance of 65.33 million yuan, which represents 5.77% of its market capitalization [1] - As of September 30, the number of shareholders for TechSource Group decreased by 56.80% to 26,900, while the average circulating shares per person increased by 131.47% to 1,444 shares [2] - For the period from January to September 2025, TechSource Group reported a revenue of 797 million yuan, reflecting a year-on-year growth of 7.58%, while the net profit attributable to shareholders decreased by 14.72% to 117 million yuan [2] Group 2 - The main business of TechSource Group includes the research, innovation, and industrialization of dietary nutritional supplements, with revenue composition as follows: nutritional raw materials 34.70%, formulations 15.24%, and various specific nutritional raw materials and formulations contributing to the total [1]

Group 1 - The core viewpoint of the news is that 技源集团 (TechSource Group) has shown a slight increase in stock price and has engaged in financing activities, indicating investor interest despite a decrease in net profit year-on-year [1][2]. Group 2 - On November 14, TechSource Group's stock rose by 0.20%, with a trading volume of 32.64 million yuan. The financing buy-in amount for the day was 3.56 million yuan, while the net financing buy-in was 1.27 million yuan, leading to a total financing and margin balance of 68.84 million yuan [1]. - As of November 14, the financing balance of TechSource Group accounted for 6.03% of its market capitalization, indicating a moderate level of leverage [1]. - The company is based in Shanghai and specializes in the research, innovation, and industrialization of dietary nutritional supplements, with a revenue composition that includes 34.70% from nutritional raw materials and 15.24% from formulations [1]. Group 3 - As of September 30, the number of shareholders for TechSource Group was 26,900, a decrease of 56.80% from the previous period, while the average circulating shares per person increased by 131.47% to 1,444 shares [2]. - For the period from January to September 2025, TechSource Group reported a revenue of 797 million yuan, reflecting a year-on-year growth of 7.58%, but the net profit attributable to shareholders decreased by 14.72% to 117 million yuan [2].

Core Insights - The 8th China International Import Expo (CIIE) held from November 5 to 10, 2025, showcased participation from 155 countries and regions, with 4,108 overseas enterprises exhibiting, marking a record exhibition area of over 430,000 square meters, reflecting China's commitment to high-level opening-up [1] - The Hong Kong brand "Xiaozhu" established a 200-square-meter "Hong Kong Traditional Medicine Pavilion" at the expo, integrating Hong Kong design with traditional herbal culture, highlighting innovative achievements in Chinese herbal wisdom [1][4] - Xiaozhu was confirmed by iResearch as the global online sales leader in the "cross-border Chinese herbal dietary supplements" category, based on comprehensive sales data analysis from major e-commerce platforms [1][3] Company Insights - Xiaozhu's dietary supplements combine traditional Chinese medicine theories with modern nutritional science, focusing on safety, long-term use, and personalized adjustments, utilizing ingredients like ginseng, astragalus, and angelica [3] - The brand emphasizes a health philosophy that prioritizes balance and gradual improvement, aligning with modern consumers' preferences for holistic health and self-repairing management [4] - Xiaozhu's innovative practices in merging traditional herbal wisdom with modern nutrition have garnered media attention, with coverage from multiple outlets, including CCTV [6] Industry Insights - The trend of integrating traditional Chinese health concepts into global health practices is gaining momentum, with Xiaozhu positioned as a key player in this movement [4] - iResearch, as a leading commercial data and research institution in China, provides professional industry research and data services, helping brands achieve business growth and strategic upgrades [9]